Wednesday, June 8, 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

We know that, PLX-4032(RG7204, Vemurafenib) is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF. BRAFV600E cancer-causing mutation occurs in most melanomas and about eight percent of all solid tumors....

More....


No comments:

Post a Comment